ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses
Part of paid clinical trials in Gainesville, Florida.
- Sponsor
- University of Florida
- Study ID
- NCT06722807
- Status
- Recruiting
Conditions
- Renal Cell Carcinoma (RCC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- sutureless, clampless partial nephrectomy — PROCEDUREAll subjects will undergo a clampless, sutureless robotic partial nephrectomy.
Study Details
During partial nephrectomy surgery, efforts at minimizing ischemia while maximizing renal parenchymal volume are desirable to preserve renal function1,2. Not only clamping of the hilum but the renorrhaphy portion of the procedure also can have a significant negative impact on renal function3-5. It is possible to perform this procedure without clamping the hilum and also without formal renorrhaphy. However robust prospective formal evaluation of safety, risks, and potential benefits and whether or not the technique can be employed in a generalized fashion has not been studied. Demonstration of safety and generalizability may open a whole new avenue of approaching nephron sparing and renal function sparing kidney surgery and decrease potential risks for long term kidney disease in patients with renal masses. This study will investigate the safety, efficacy, and generalizability of the use of clampless, sutureless partial nephrectomy in the treatment of renal cell carcinoma.
Key Dates
- Start date
- Jun 10, 2025
- Status verified
- Jun 2026
- Primary completion
- Aug 31, 2026
- Completion
- Jan 31, 2027
Study Design
- Enrollment
- 59 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Clampless, sutureless robotic partial nephrectomy
Primary Outcome Measure
Positive margin rate [ Time Frame: 2-3 weeks post-surgery ]
Central Contacts
- Pravalika Manda(352) 265-9728
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32610 | Padraic O'Malley (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Gainesville, FL
Related Studies
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona
- Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More TreatmentPHASE2 · Recruiting · Advenchen Pharmaceuticals, LLC. · Birmingham, Alabama
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)PHASE1/PHASE2 · Recruiting · GI Innovation, Inc. · Scottsdale, Arizona
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerPHASE3 · Recruiting · Alliance for Clinical Trials in Oncology · Phoenix, Arizona